The findings revealed the following cumulative risks: colorectal cancer—46%, 43%, and 15% for MLH1, MSH2, and MSH6 gene mutations carriers, respectively; endometrial cancer—43%, 57%, and 46%; ovarian cancer—10%, 17%, and 13%; upper gastrointestinal cancers—21%, 10%, and 7%; urinary tract cancers—8%, 25%, and 11%; prostate cancer—17%, 32%, and 18%; and brain tumors—1%, 5%, and 1% [24]. This evidence concerns the gene MSH2 and ovarian cancer.